A wide range of 5–90% BRCA1 promoter hypermethylation among ovarian cancer cases has been reported in the past [1, 30, 31, 32, 33, 34]; the wide variability is possibly the consequence of different detection techniques, cohort selection criteria, and/or material sources (i.e., tissue vs. cfDNA). This evidence concerns the gene BRCA1 and ovarian cancer.